Filing Flows › Editas Medicine (EDIT) › Q1 2026 › vs Q1 2025
Editas Medicine (EDIT) Q1 2026 vs Q1 2025 (year over year)
Editas Medicine's revenue fell $1.8M (-39%) from $4.7M in Q1 2025 to $2.8M in Q1 2026.
Editas Medicine, Q1 2026: revenue $2.8M (-39% year over year), operating margin -883.2%, net loss $25.0M, operating cash flow −$23.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.8M | $4.7M | −$1.8M | -39% |
| Other income, net | $21K | $75K | −$54K | -72% |
| Net loss | $25.0M | $76.1M | −$51.1M | -67% |
| Costs & expenses | $27.8M | $80.8M | −$53.0M | -66% |
| Operating costs | $27.8M | $80.8M | −$53.0M | -66% |
| Research & development | $17.6M | $26.6M | −$9.0M | -34% |
| General & admin | $10.2M | $13.4M | −$3.1M | -23% |
| Operating cash sources | $25.6M | $52.7M | −$27.0M | -51% |
| Depreciation | $483K | $1.9M | −$1.4M | -75% |
| Share-based compensation | $2.1M | $3.0M | −$877K | -29% |
| Cash used in operations | $23.1M | $47.8M | −$24.7M | -52% |
| Net loss absorbed | $25.0M | $76.1M | −$51.1M | -67% |
| Working capital & other | $664K | −$23.4M | $24.1M | — |
Questions
How much did Editas Medicine's revenue grow year over year in Q1 2026?
Editas Medicine's revenue fell $1.8M (-39%) from $4.7M in Q1 2025 to $2.8M in Q1 2026.